Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
Previous Symbol
CUSIPN/A
Phone206-788-4545
Debt
Debt-to-Equity Ratio0.05
Current Ratio9.20
Quick Ratio9.20
Price-To-Earnings
Trailing P/E Ratio-3.99
Forward P/E Ratio-1.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales38.35
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.68 per share
Price / Book0.84
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-7,780,000.00
Net Margins-1,602.19%
Return on Equity-43.25%
Return on Assets-39.08%
Miscellaneous
Employees38
Outstanding Shares13,850,000
Market Cap$66.32 million
OptionableNot Optionable
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences Inc (NASDAQ:ALPN) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.31. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. View Alpine Immune Sciences' Earnings History.
When is Alpine Immune Sciences' next earnings date?
What price target have analysts set for ALPN?
5 analysts have issued 1 year target prices for Alpine Immune Sciences' shares. Their predictions range from $12.00 to $13.00. On average, they expect Alpine Immune Sciences' share price to reach $12.80 in the next twelve months. This suggests a possible upside of 167.2% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.
What is the consensus analysts' recommendation for Alpine Immune Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.
Has Alpine Immune Sciences been receiving favorable news coverage?
Media coverage about ALPN stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alpine Immune Sciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Athersys (ATHX), Verrica Pharmaceuticals (VRCA), Merus (MRUS), Magenta Therapeutics (MGTA), Syros Pharmaceuticals (SYRS), Tocagen (TOCA), BioDelivery Sciences International (BDSI), AVEO Pharmaceuticals (AVEO), Affimed (AFMD), Catalyst Pharmaceuticals (CPRX), Arbutus Biopharma (ABUS), Neptune Wellness Solutions (NEPT), Aldeyra Therapeutics (ALDX), Intec Pharma (NTEC) and Ocular Therapeutix (OCUL).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 50)
- Dr. Stanford Peng, Exec. VP of R&D and Chief Medical Officer (Age 47)
- Dr. Mark J. Litton, Pres & COO (Age 50)
- Mr. Paul Rickey, Sr. VP & CFO (Age 39)
- Dr. Kristine Swiderek Ph.D., Sr. VP of Research
Who are Alpine Immune Sciences' major shareholders?
Alpine Immune Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.65%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.
Which institutional investors are buying Alpine Immune Sciences stock?
ALPN stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $4.79.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $66.32 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.
What is Alpine Immune Sciences' official website?
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
